imatinib mesylate has been researched along with Eosinophilic Leukemia, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barraco, D; Candoni, A; Carobolante, F; Fanin, R; Piccaluga, P; Simeone, E; Tabanelli, V | 1 |
| Haba, Y; Hanzawa, K; Itoyama, S; Kizaki, M; Mori, S; Nemoto, T; Sagawa, M; Saito, Y; Sekiguchi, Y; Tamaru, J; Tokuhira, M; Tomikawa, A; Watanabe, R | 1 |
2 other study(ies) available for imatinib mesylate and Eosinophilic Leukemia, Acute
| Article | Year |
|---|---|
Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers; Bone and Bones; Bone Marrow; Humans; Imatinib Mesylate; Leukemia, Eosinophilic, Acute; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2014 |
[Acute-onset eosinophilic leukemia associated with tumor lysis syndrome after imatinib and steroid pulse therapy].
Topics: Acute Kidney Injury; Aged, 80 and over; Benzamides; Disseminated Intravascular Coagulation; Drug Synergism; Fatal Outcome; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Eosinophilic, Acute; Methylprednisolone; Piperazines; Pleural Effusion; Pulse Therapy, Drug; Pyrimidines; Tumor Lysis Syndrome | 2010 |